Association between lipoprotein-associated phospholipase A2 and lower extremity arterial disease in type 2 diabetes mellitus

Xu, Xinyue; Li, Guo; Wang, Qian; Yu, Xuebing; Li, Ling; Wei, Qiong

doi:10.1016/j.cca.2020.07.023

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lp-PLA2 is an enzyme released from macrophages which hydrolyzes oxidized phospholipids on LDL lipoproteins. Its activity leads to the release of several proinflammatory agents that contribute to endothelial damage and atherosclerosis [30]. The majority of published studies indicate that patients infected with SARS-CoV-2, especially those with a severe course of the disease, express an increased concentration of Lp-PLA2 [31][32][33].…”

Section: Discussionmentioning

confidence: 99%

Organ-Dysfunction Markers in Mild-to-Moderate COVID-19 Convalescents

Wiśniewska,

Kijak,

Nowak

et al. 2024

JCM

View full text Add to dashboard Cite

Background: A coronavirus disease 2019 (COVID-19) outbreak led to a worldwide pandemic. COVID-19 not only caused acute symptoms during the severe phase of the disease, but also induced long-term side effects on the functioning of many organs and systems. Symptoms that were associated with the disease and present at least 3 months after recovery were named long COVID. The aim of this study was to assess if mild-to-moderate COVID-19 may lead to the dysfunction of respiratory, cardiovascular, neural, and renal systems in healthy blood donors who recovered from the disease at least 6 months earlier. Methods: Here, we examined 294 adults among volunteer blood donors divided into convalescents (n = 215) and healthy controls (n = 79). Concentrations of soluble CD163, TGF beta, Lp-PLA2, NCAM-1, S100, NGAL, and creatinine were measured either by ELISA or automated methods. The probability value p < 0.05 was considered as statistically significant. Results: We found significant differences in Lp-PLA2, S100, and NCAM-1 between convalescents and never-infected subjects. Lp-PLA2 and NCAM-1 were lower, and S100 higher, in convalescents than in the control group. Conclusion: Mild-to-moderate COVID-19 convalescents are at a low risk of developing lung fibrosis or chronic kidney disease. However, they should regularly carry out their prophylaxis examinations for early detection of possible negative outcomes of COVID-19.

show abstract